Simcere Pharmaceutical, Connect Biopharma's exclusive licensee in China, submitted a New Drug Application (NDA) for rademikibart to the National Medical Products Administration of China (NMPA). The application is for the treatment of atopic dermatitis (AD) in adults and adolescents.
Under the existing license agreement, Connect Biopharma is eligible to receive milestone payments totaling approximately $110 million upon the achievement of specific development, regulatory, and commercial milestones. The company is also eligible for tiered royalties up to low double-digit percentages on net sales in Greater China.
The atopic dermatitis market in China represents a significant opportunity, with an estimated 70 million patients. This regulatory submission by Simcere marks a key step towards potential commercialization in the region and future revenue generation for Connect Biopharma.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.